Rarecells
Rarecells, Inc. is a healthcare company specializing in early cancer detection through its proprietary ISET® liquid biopsy technology. The company develops and commercializes non-invasive blood tests that detect rare circulating tumor cells from any cancer type, enabling diagnosis at very early stages. Their technology combines morpho-molecular scanning, immune-morpho molecular analyses, image analysis, and artificial intelligence to identify cancer cells with high sensitivity. Rarecells operates globally with research origins in France and a presence in the United States, collaborating with leading universities and research centers. The company is led by a team of experienced scientists and executives and holds over 49 patents with more than 125 scientific publications validating their technology. Rarecells partners with diagnostic and pharmaceutical companies to bring life-saving cancer tests to patients, aiming to transform cancer care by enabling earlier, less invasive, and more effective treatment.
Rarecells
Rarecells, Inc. is a healthcare company specializing in early cancer detection through its proprietary ISET® liquid biopsy technology. The company develops and commercializes non-invasive blood tests that detect rare circulating tumor cells from any cancer type, enabling diagnosis at very early stages. Their technology combines morpho-molecular scanning, immune-morpho molecular analyses, image analysis, and artificial intelligence to identify cancer cells with high sensitivity. Rarecells operates globally with research origins in France and a presence in the United States, collaborating with leading universities and research centers. The company is led by a team of experienced scientists and executives and holds over 49 patents with more than 125 scientific publications validating their technology. Rarecells partners with diagnostic and pharmaceutical companies to bring life-saving cancer tests to patients, aiming to transform cancer care by enabling earlier, less invasive, and more effective treatment.
TL;DR
What they do: Develop ultra‑sensitive ISET® liquid biopsy tests to detect circulating tumor cells for very early cancer detection
Founded: 2010–2012 (founding year reported as 2010 and 2012 in sources)
Headquarters / labs: New York (headquarters) with offices/labs in Paris
Technology: ISET® platform combining morpho‑molecular analysis, image analysis, and AI
Series A (latest round reported Dec 9, 2021); investors reported include AA Sons and Globivest
